Home / Longevity / Cardiogen
CrAnimal studies only

Cardiogen protocol

Cardiogen is a 4-amino-acid peptide (Ala-Glu-Asp-Arg) from a Russian research group. It has been tested in heart tissue cultures and rats. I found no human study.

Not approved as a medicineLab and animal studies only
ProtocolMixingResultsSide effectsHow it worksSources

The protocol at a glance

There is no human dose, and none of the sources give one.

ItemWhat the sources show
Human doseNot established
Studied inRat heart tissue cultures and rats

Do not confuse it with CardioGen-82, an unrelated heart-scan agent. ClinicalTrials.gov lists no Cardiogen peptide trial (searched 5 Nov 2026).

Community reports

gives no human dose for Cardiogen. They say they will not give one.

What people say they do, collected from community discussions. Not tested in a trial; shown so you can compare it with the evidence above.

Mixing

No mixing table here: this one is used as a capsule, nasal spray or skin product, or has no human amount to calculate from. The general mixing calculator works for any vial.

What the trials found

No human results exist. Animal and tissue findings:

0Human trials found
Tissue cultureAt a very low concentration, rat heart tissue grew more and the p53 marker fell (young and old rats)
RatsInjections slowed a transplanted tumor in older rats in a dose-dependent way

Bull Exp Biol Med 2009 (PMID 20396706); Adv Gerontol 2009 (PMID 20210190); Adv Gerontol 2006 (PMID 17152728).

Side effects

  • No human safety data exists.

How it works

Cell growth in culture

In rat heart tissue cultures it raised cell growth and lowered p53, a marker of cell death.

Sources

  • Effect of amino acids and Cardiogen on rat myocardial tissue culture. Adv Gerontol 2009, PMID 20210190
  • Tumor-modifying effect of Cardiogen on M-1 sarcoma in senescent rats. Bull Exp Biol Med 2009, PMID 20396706
  • Tissue-specific effect of synthetic peptides in organotypic culture. Adv Gerontol 2006, PMID 17152728
  • ClinicalTrials.gov search by intervention name, run 5 Nov 2026: no Cardiogen peptide trial